Patents by Inventor Unmesh Shah

Unmesh Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Training a neural network using periodic sampling over model weights
    Patent number: 11922316
    Abstract: A computer-implemented method includes: initializing model parameters for training a neural network; performing a forward pass and backpropagation for a first minibatch of training data; determining a new weight value for each of a plurality of nodes of the neural network using a gradient descent of the first minibatch; for each determined new weight value, determining whether to update a running mean corresponding to a weight of a particular node; based on a determination to update the running mean, calculating a new mean weight value for the particular node using the determined new weight value; updating the weight parameters for all nodes based on the calculated new mean weight values corresponding to each node; assigning the running mean as the weight for the particular node when training on the first minibatch is completed; and reinitializing running means for all nodes at a start of training a second minibatch.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: March 5, 2024
    Assignee: LG ELECTRONICS INC.
    Inventors: Samarth Tripathi, Jiayi Liu, Unmesh Kurup, Mohak Shah
  • Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists
    Patent number: 11161819
    Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: November 2, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gregory L. Adams, Jason M. Cox, John S. Debenham, Scott Edmondson, Eric J. Gilbert, Yan Guo, Yu Jiang, Hubert Josien, Hyunjin M. Kim, Ping Lan, Shouwu Miao, Christopher W. Plummer, Murali Rajagopalan, Unmesh Shah, Zhongxiang Sun, Quang T. Truong, Feroze Ujjainwalla, Francisco Velazquez, Srikanth Venkatraman, Takao Suzuki, Nengxue Wang
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS
    Publication number: 20200347020
    Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: July 22, 2020
    Publication date: November 5, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gregory L. Adams, Jason M. Cox, John S. Debenham, Scott Edmondson, Eric J. Gilbert, Yan Guo, Yu Jiang, Hubert Josien, Hyunjin M. Kim, Ping Lan, Shouwu Miao, Christopher W. Plummer, Murali Rajagopalan, Unmesh Shah, Zhongxiang Sun, Quang T. Truong, Feroze Ujjainwalla, Francisco Velazquez, Srikanth Venkatraman, Takao Suzuki, Nengxue Wang
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS
    Publication number: 20190161448
    Abstract: The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: May 19, 2017
    Publication date: May 30, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gregory L. Adams, Jason M. Cox, John S. Debenham, Scott Edmondson, Eric J. Gilbert, Yan Guo, Yu Jiang, Hubert Josien, Hyunjin M. Kim, Ping Lan, Shouwu Miao, Christopher W. Plummer, Murali Rajagopalan, Unmesh Shah, Zhongxiang Sun, Quang T. Truong, Feroze Ujjainwalla, Francisco Velazquez, Srikanth Venkatraman, Takao Suzuki, Nengxue Wang
  • Substituted spiropiperidinyl compounds useful as GPR120 agonists
    Patent number: 9708270
    Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: July 18, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mariappan Chelliah, Hong Dong Chu, Jason M. Cox, John S. Debenham, Keith Eagen, Ping Lan, Clare London, Michael A. Plotkin, Unmesh Shah, Christopher Joseph Sinz, Zhongxiang Sun, Henry M. Vaccaro, Srikanth Venkatraman
  • HCV NS3 protease inhibitors
    Patent number: 9328138
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 3, 2016
    Assignees: MSD Italia S.R.L., Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, John McCauley, Nigel Liverton, Christiane Grisé-Bard, Marie-Christine Brochu, Sylvie Charron, Virender Aulakh, Benoit Bachand, Patrick Beaulieu, Helmi Zaghdane, Yongxin Han, Marco Ferrara, Steven Harper, Vincenzo Summa, Samuel Chackalamannil, Srikanth Venkatraman, Unmesh Shah, Francisco Velazquez
  • SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS
    Publication number: 20150274672
    Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mariappan Chelliah, Hong Dong Chu, Jason M. Cox, John S. Debenham, Keith Eagen, Ping Lan, Clare London, Michael A. Plotkin, Unmesh Shah, Christopher Joseph Sinz, Zhongxiang Sun, Henry M. Vaccaro, Srikanth Venkatraman
  • Morpholinone compounds as factor IXA inhibitors
    Patent number: 8987242
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: March 24, 2015
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceuticals Co., Ltd.
    Inventors: Samuel Chackalamannil, Tin-Yau Chan, Mariappan V. Chelliah, Martin C. Clasby, Michael Dwyer, William J. Greenlee, Tomokazu Hirabayashi, Santhosh Neelamkavil, Hidemitsu Nishida, Fumihiko Saitoh, Unmesh Shah, Yan Xia
  • HCV NS3 protease inhibitors
    Patent number: 8987195
    Abstract: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: March 24, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Thomas Bara, Sathesh Bhat, Dipshikha Biswas, Linda Brockunier, Duane A. Burnett, Samuel Chackalamannil, Mariappan V. Chelliah, Austin Chen, Martin Clasby, Vince J. Colandrea, Zhuyan Guo, Yongxin Han, Charles Jayne, Hubert Josien, Karen Marcantonio, Shouwu Miao, Santhosh Neelamkavil, Patrick Pinto, Murali Rajagopalan, Unmesh Shah, Francisco Velazquez, Srikanth Venkatraman, Yan Xia
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20140296136
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 2, 2014
    Inventors: Michael T. Rudd, John McCauley, Nigel Liverton, Christiane Grisé-Bard, Marie-Christine Brochu, Sylvie Charron, Virender Aulakh, Benoit Bachand, Patrick Beaulieu, Helmi Zaghdane, Yongxin Han, Marco Ferrara, Steven Harper, Vincenzo Summa, Samuel Chackalamannil, Srikanth Venkatraman, Unmesh Shah, Francisco Velazquez
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20140057836
    Abstract: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
    Type: Application
    Filed: August 6, 2013
    Publication date: February 27, 2014
    Inventors: Thomas BARA, Sathesh Bhat, Dipshika Biswas, Linda Brockunier, Duane Burnette, Samuel Chackalamannil, Mariappan Vasu Cheliah, Austin Chen, Martin Clasby, Vince J. Colandrea, Zhuyan Guo, Yongxin Han, Charles Jayne, Hubert Josien, Karen Marcantonio, Shouwu Miao, Santhosh Neelamkavil, Patrick Pinto, Murali Rajogopalan, Unmesh Shah, Francisco Velazquez, Srikanth Venkatraman, Yan Xia
  • Substituted bicyclic piperidinyl- and piperazinyl-sulfonamides useful to inhibit 11?-hydroxysteroid dehydrogenase type-1
    Patent number: 8604195
    Abstract: In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11?-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11?-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: December 10, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Unmesh Shah, Craig D. Boyle, Samuel Chackalamannil
  • 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11?-hydroxysteroid dehydrogenase type-I
    Patent number: 8466149
    Abstract: In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11?-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11?-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: June 18, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig D. Boyle, Samuel Chackalamannil, Unmesh Shah, Claire M. Lankin
  • 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-E]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
    Patent number: 8389532
    Abstract: The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: March 5, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig D. Boyle, Samuel Chackalamannil, Unmesh Shah, Jean E. Lachowicz
  • BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20120040975
    Abstract: The present invention relates to Bridged Bicyclic Heterocycle Derivatives, compositions comprising a Bridged Bicyclic Heterocycle Derivative, and methods of using the Bridged Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.
    Type: Application
    Filed: April 1, 2010
    Publication date: February 16, 2012
    Inventors: Santhosh Francis Neelamkavil, Bernard R. Neustadt, Andrew Stamford, Yan Xia, Joel M. Harris, Craig D. Boyle, Samuel Chackalamannil, Dipshikha Biswas, Hong Liu, Jinsong Hao, Claire M. Lankin, Unmesh Shah
  • 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1
    Publication number: 20110237559
    Abstract: In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11?-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11?-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: August 12, 2008
    Publication date: September 29, 2011
    Applicant: Schering Corporation
    Inventors: Craig D. Boyle, Samuel Chackalamannil, Unmesh Shah, Claire M. Lankin
  • MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS
    Publication number: 20110135650
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: June 1, 2010
    Publication date: June 9, 2011
    Inventors: Samuel CHACKALAMANNIL, Tin-Yau CHAN, Mariappan V. CHELLIAH, Martin C. CLASBY, Michael DWYER, William J. GREENLEE, Tomokazu HIRABAYASHI, Santhosh NEELAMKAVIL, Hidemitsu NISHIDA, Fumihiko SAITOH, Unmesh SHAH, Yan XIA
  • SUBSTITUTED BICYCLIC PIPERIDINYL-AND PIPERAZINYL- SULFONAMIDES USEFUL TO INHIBIT 11beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1
    Publication number: 20110059929
    Abstract: In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11?-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11?-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: August 12, 2008
    Publication date: March 10, 2011
    Inventors: Unmesh Shah, Craig D. Boyle, Samuel Chackalamannil
  • 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5-AMINE
    Publication number: 20090270432
    Abstract: The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
    Type: Application
    Filed: July 6, 2009
    Publication date: October 29, 2009
    Inventors: Craig D. Boyle, Samuel Chackalamannil, Unmesh Shah, Jean E. Lachowicz
  • 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
    Patent number: 7572802
    Abstract: The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: August 11, 2009
    Assignee: Schering Corporation
    Inventors: Craig D. Boyle, Samuel Chackalamannil, Unmesh Shah, Jean E. Lachowicz